3,016 research outputs found
Evidence of Positive Selection for a Glycogen Synthase (GYS1) Mutation in Domestic Horse Populations
No full textSupplementary data for publication: McCoy AM, Schaefer R, Petersen JL, Morrell PL, Slamka MA, Mickelson JR, Valberg SJ, McCue ME (2013). Evidence of Positive Selection for a Glycogen Synthase (GYS1) Mutation in Domestic Horse Populations Journal of Heredity, 2013. doi: 10.1093/jhered/est075
Evidence of Positive Selection for a Glycogen Synthase (GYS1) Mutation in Domestic Horse Populations
No full textSupplementary data for publication: McCoy AM, Schaefer R, Petersen JL, Morrell PL, Slamka MA, Mickelson JR, Valberg SJ, McCue ME (2013). Evidence of Positive Selection for a Glycogen Synthase (GYS1) Mutation in Domestic Horse Populations Journal of Heredity, 2013. doi: 10.1093/jhered/est075
Evidence of Positive Selection for a Glycogen Synthase (GYS1) Mutation in Domestic Horse Populations
No full textSupplementary data for publication: McCoy AM, Schaefer R, Petersen JL, Morrell PL, Slamka MA, Mickelson JR, Valberg SJ, McCue ME (2013). Evidence of Positive Selection for a Glycogen Synthase (GYS1) Mutation in Domestic Horse Populations Journal of Heredity, 2013. doi: 10.1093/jhered/est075
Reflections of a Jewish, Lesbian Author
No full textIn this essay, Jewish lesbian author Leslea Newman speaks of the importance of finding one's own identity reflected in works of literature, citing examples of her own work, and recommending the writings of other Jewish lesbian authors of merit
Assessing the empirical validity of alternative multi-attribute utility measures in the maternity context
No full textMulti-attribute utility measures are preference-based health-related quality of life measures that have been developed to inform economic evaluations of health care interventions. The objective of this study was to compare the empirical validity of two multi-attribute utility measures (EQ-5D and SF-6D) based on hypothetical preferences in a large maternity population in England
Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease.
No full textBACKGROUND: Morbidity in COPD results from a combination of factors including hypoxia-induced pulmonary hypertension, in part due to pulmonary vascular remodelling. Animal studies suggest a role of angiotensin II and acute studies in man concur. Whether chronic angiotensin-II blockade is beneficial is unknown. We studied the effects of an angiotensin-II antagonist losartan, on haemodynamic variables, exercise capacity and symptoms. METHODS: This was a double-blind, randomized, parallel group, placebo- controlled study of 48 weeks duration. Forty patients with COPD and pulmonary hypertension (Tran tricuspid pressure gradient (TTPG) = 30 mmHg) were randomised to losartan 50 mg or placebo. Changes in TTPG were assessed at 3, 6 and 12 months. RESULTS: There was a trend for TTPG to increase in the placebo group (baseline 43.4 versus 48.4 mmHg at endpoint) and stay constant in the losartan group (baseline 42.8 versus 43.6 mmHg). More patients in the losartan group (50%) than in the placebo group (22%) showed a clinically meaningful reduction in TTPG at any timepoint; these effects seemed more marked in patients with higher baseline TTPG. There were no clear improvements in exercise capacity or symptoms. CONCLUSION: In this 12-month pilot study, losartan 50 mg had no statistically significant beneficial effect on TTPG, exercise capacity or symptoms in pulmonary hypertension secondary to obstructive disease. A sub-group of patients with higher TTPG may benefit
Staging the life-world: Habermas and the recuperation of Austin speech act theory
No full textPT: J; CR: APEL KO, 1976, SPRACHPRAGMATIK PHIL AUSTIN JL, 1962, HOW TO DO THINGS WOR AUSTIN JL, 1970, PHILOS PAPERS CULLER J, 1982, DECONSTRUCTION DERRIDA J, 1977, GLYPH, V1 ECO U, 1992, UNDERSTANDING ORIGIN, P273 FISH S, 1987, TRACING LIT THEORY HABERMAS J, 1984, THEORY COMMUNICATIVE, V1 HABERMAS J, 1987, THEORY COMMUNICATIVE, V2 HABERMAS J, 1989, JURGEN HABERMAS SOC MARTINET A, 1962, FUNCTIONAL VIEW LANG, P24 QUINE WV, 1960, WORD OBJECT SEARLE JR, 1969, SPEECH ACTS SEARLE JR, 1977, GLYPH, V1 VANEEMEREN F, 1983, SPEECH ACTS ARGUMENT WARNOCK GJ, 1989, FL AUSTIN; NR: 16; TC: 0; J9: J THEOR SOC BEHAV; PG: 12; GA: KR147Source type: Electronic(1
MODEIN2 and Colby: computer codes for sediment transport computations
No full textNovember, 1976.CER76-77VMP-JL-DBS19
Tunneling microscopy of NbSe2 in air
No full textPT: J; CR: BANDO H, 1987, JPN J APPL PHYS PT 2, V26, L41 BINNIG G, 1982, PHYS REV LETT, V49, P57 BRYANT A, 1986, APPL PHYS LETT, V48, P832 FELDMAN JL, 1976, J PHYS CHEM SOLIDS, V37, P1141 FELDMAN JL, 1981, J PHYS CHEM SOLIDS, V42, P1029 JERICHO MH, 1980, PHYS REV B, V22, P4907 JERICHO MH, 1987, REV SCI INSTRUM, V58, P1349 MAMIN HJ, 1986, PHYS REV B, V34, P9015 PETHICA JB, 1986, IBM J RES DEV, V30, P455 RAO GVS, 1979, PHYSICS CHEM MATERIA, P99 SOLER JM, 1986, PHYS REV LETT, V57, P444 TERSOFF J, 1986, PHYS REV LETT, V57, P440 TOKUMOTO H, 1986, JPN J APPL PHYS, V25, L621; NR: 13; TC: 14; J9: J APPL PHYS; PG: 4; GA: L5219Source type: Electronic(1
Absence of xenotropic murine leukaemia virus-related virus in UK patients with chronic fatigue syndrome
No full textBackground: Detection of a retrovirus, xenotropic murine leukaemia virus-related virus (XMRV), has recently been reported in 67% of patients with chronic fatigue syndrome. We have studied a total of 170 samples from chronic fatigue syndrome patients from two UK cohorts and 395 controls for evidence of XMRV infection by looking either for the presence of viral nucleic acids using quantitative PCR (limit of detection <16 viral copies) or for the presence of serological responses using a virus neutralisation assay.
Results: We have not identified XMRV DNA in any samples by PCR (0/299). Some serum samples showed XMRV neutralising activity (26/565) but only one of these positive sera came from a CFS patient. Most of the positive sera were also able to neutralise MLV particles pseudotyped with envelope proteins from other viruses, including vesicular stomatitis virus, indicating significant cross-reactivity in serological responses. Four positive samples were specific for XMRV.
Conclusions: No association between XMRV infection and CFS was observed in the samples tested, either by PCR or serological methodologies. The non-specific neutralisation observed in multiple serum samples suggests that it is unlikely that these responses were elicited by XMRV and highlights the danger of over-estimating XMRV frequency based on serological assays. In spite of this, we believe that the detection of neutralising activity that did not inhibit VSV-G pseudotyped MLV in at least four human serum samples indicates that XMRV infection may occur in the general population, although with currently uncertain outcomes
- …
